Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Citigroup analyst Joanne Wuensch downgrades Nevro (NYSE:NVRO) from Neutral to Sell and lowers the price target from $13.5 to...
Canaccord Genuity analyst William Plovanic maintains Nevro (NYSE:NVRO) with a Hold and lowers the price target from $17 to $11.
Wells Fargo analyst Nathan Treybeck maintains Nevro (NYSE:NVRO) with a Equal-Weight and lowers the price target from $14 to ...
Piper Sandler analyst Adam Maeder maintains Nevro (NYSE:NVRO) with a Underweight and lowers the price target from $15 to $12.
Nevro is raising its adjusted EBITDA guidance for the full-year 2024 to a range of negative $5 million to positive $2 million f...
Nevro (NYSE:NVRO) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(1.08) by 35.19 ...
RBC Capital analyst Shagun Singh maintains Nevro (NYSE:NVRO) with a Sector Perform and lowers the price target from $18 to $16.
Mizuho analyst Anthony Petrone maintains Nevro (NYSE:NVRO) with a Neutral and lowers the price target from $20 to $16.
